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ABSTRACT
Human APOBEC3F and APOBEC3G are double-
domained deaminases that can catalyze dC!dU
deamination in HIV-1 and MLV retroviral DNA replica-
tion intermediates, targeting T–C or C–C dinucleo-
tides, respectively. HIV-1 antagonizes their action
through its vif gene product, which has been shown
(at least in the case of APOBEC3G) to interact with
the N-terminal domain of the deaminase, triggering
its degradation. Here, we compare APOBEC3F and
APOBEC3G to APOBEC3C, a single-domained deam-
inasethatcanalsoactonbothHIV-1andMLV.Wefind
that whereas APOBEC3C contains all the information
necessary for both Vif-binding and cytidine deam-
inase activity in a single domain, it is the C-terminal
domain of APOBEC3F and APOBEC3G that confer
their target site specificity for cytidine deamination.
We have exploited the fact that APOBEC3C, whilst
highly homologous to the C-terminal domain of
APOBEC3F, exhibits a distinct target site specificity
(preferring Y–C dinucleotides)inordertoidentifyresi-
dues in APOBEC3F that might affect its target site
specificity. We find that this specificity can be altered
by single amino acid substitutions at several distinct
positions, suggesting that the strong dependence
of APOBEC3-mediated deoxycytidine deamination
on the 50-flanking nucleotide is sensitive to relatively
subtle changes in the APOBEC3 structure. The
approach has allowed the isolation of APOBEC3 DNA
mutators that exhibit novel target site preferences.
INTRODUCTION
APOBEC3G (which has also been named CEM15) was
discovered as an element capable of restricting infection of
the non-permissive T-cell line CEM by Vif-deﬁcient HIV-1
particles (1). In wild-type HIV-1, the virus-encoded Vif
protein counteracts the anti-viral effect of APOBEC3G by
inducing its poly-ubiquitination and subsequent proteasome-
mediated degradation (2–6). An aspartic acid residue in the
ﬁrst domain of human APOBEC3G (position 128) is critical
for the interaction with and sensitivity to Vif (7–10). In the
absence of a Vif-interaction, APOBEC3G is encapsidated in
HIV-1 [and can similarly be encapsidated by Moloney leuk-
emia virus (MLV)] through binding to the retroviral gag poly-
peptide and, more speciﬁcally, to the nucleocapsid-forming
region in the case of HIV-1 (11–15). The APOBEC3G protein
that has been incorporated into the virion then acts in the target
cell to deaminate deoxycytidines (dC) in the minus-strand
retroviral cDNA replication intermediate (16–20). This deam-
ination is not random: dC residues targeted by APOBEC3G
are nearly always preceded by a 50-dC residue (16,17,21,22).
Whilst evidence of retroviral restriction by APOBEC3G
largely rests on in vitro co-transfection assays carried out
with artiﬁcial retroviral constructs, support for the idea that
host-mediated deamination of retroviral replication interme-
diates can actually occur during clinical HIV-1 infection is
indicated by the observation that tonic G!A hypermutation
(that can be ascribed to dC!dU deamination of minus-strand
cDNA) is frequently observed in natural isolates of HIV-1
(23–27). However, the pattern of G!A substitutions exhibited
by naturally occurring hypermutated HIV-1 sequences indic-
ates that APOBEC3G is not the only cytidine deaminase that
attacks HIV-1. Hypermutation is observed at both GG and
GA dinucleotides in the retroviral genome consistent with
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cDNA. Indeed, recent work has revealed that other members
of the human APOBEC3 family apart from APOBEC3G can
act on HIV-1 (28–33).
The human APOBEC3 family of cytidine deaminases
comprises seven genes (A to D and F to H) that are encoded
in a cluster located on chromosome 22 (34–37). In all cases,
they contain either one or two copies of a core motif that
is typical to all cytidine deaminases: HXE-X24–30-PCXXC
(34,38–40). Previous studies on E.coli cytidine deaminase
(ECCDA) propose that the histidine and two cysteines in
thismotifenableZn
2+coordination,whilsttheglutamateserves
asaprotondonorinthedeaminationprocess(41–43).Whereas
APOBEC3A, C and H have but a single zinc binding domain,
APOBEC3B, -D, -F and -G are double-domained proteins,
containingtwocopiesofthezinc-coordinationmotif.Although
the double-domained APOBEC3G is the most studied of
these deaminases, it has not yet been fully resolved as to
whether one of its two deaminase domains plays a dominant
role in retroviral restriction/deamination (17,20,44).
Recent evidence has now revealed that, in addition to APO-
BEC3G, the double-domained deaminases APOBEC3B and
APOBEC3F can also be incorporated into HIV-1 virions and
deaminate retroviral minus-strand cDNA (28–31,33). Indeed,
their mutation spectra could account for much, if not all, of the
hypermutation seen at TC dinucleotides (28–31,33).
With regard to single domained APOBEC3’s, we have pre-
viously shown that human APOBEC3C (which is highly
homologous to the second domain of human APOBEC3F)
is capable of deaminating dC in DNA as judged by a bacterial
mutation assay (21). Whilst APOBEC3C did not exhibit any
strong restricting activity against HIV-1 or MLV in earlier
comparisons of the anti-retroviral activity of APOBEC3 fam-
ily members (28–31,33), recent results from Yu et al. (29)
reveal that APOBEC3C can act as a potent inhibitor of SIV
inhibition. In fact, we ﬁnd that whilst APOBEC3C is certainly
less potent than APOBEC3F and APOBEC3G, it can clearly
act to deaminate MLV (as well as HIV-1) retroviral replication
intermediates, with a characteristic target site preference. This
has allowed us to use an MLV-based assay to perform a muta-
genesis and domain-swap comparison of APOBEC3C and
APOBEC3F that give insight into amino acid residues that
affect their target site speciﬁcity.
MATERIALS AND METHODS
Cells and vectors
TheCEM-SS cellline was obtained from the National Institute
for Biological Standards and Control, Herts, UK and main-
tained in RPMI supplemented with 10% fetal calf serum
(FCS), penicillin and streptomycin. 293T cells were cultured
in DMEM supplemented with 10% FCS, penicillin and strep-
tomycin. Whilst 293T cells express endogenous APOBEC3C
and APOBEC3F(but notAPOBEC3G) asjudgedby RT–PCR,
northern blot analysis reveals that the abundance of these
transcripts is very low and is augmented several orders of
magnitude following transfection. MLV and HIV-1-like
viruses were generated using a three-plasmid expression sys-
tem employing a HIV-1 or MLV shuttle vector, a Gag-Pol
expresser and a vector encoding the envelope glycoprotein
VSV-G. The self-inactivating HIV-1 packageable vector
CSGW encodes eGFP expressed from a SFFV 50LTR pro-
moter (45,46). HIV-1 Gag-Pol expression plasmids with
(p8.2) or without (p8.9) vif were previously described (47).
CSGW, p8.2 and p8.9 were generously donated by Greg
Towers, Wohl Virion Centre, London, UK. The pVif, pDVif,
M5P (MLV packageable genome), pOGP (MLV Gag-Pol
expresser) and pMDG (VSV-G) expression vectors were
described here (6,16). The pVif vector expresses Vif under
the control of a CMV promoter. The pDVif plasmid expresses
only the 20 ﬁrst amino acids of Vif (6).
Constructs
Generation of vectors coding for eGFP-tagged APOBEC3s is
described here (6). A FLAG-tag expression vector was gen-
erated by removing the eGFP cassette from the pEGFP-C3
plasmid (Invitrogen) and replacing it by a FLAG sequence
at the NheI and ScaI sites. Flag-tagged APOBEC3 expression
vectors were generated by subcloning the corresponding
APOBEC coding sequence obtained from the pEGFP-
APOBEC3G, -APOBEC3F and -APOBEC3C plasmids into
the XhoI and PstI sites of the FLAG-tag expression vector.
APOBEC3F mutants were made using an embedded and over-
lapping primer technique. Primer sequences are presented in
Table S1.
APOBEC3 chimeras were made by PCR ampliﬁcation
of each separate domain of APOBEC3C, APOBEC3F and
APOBEC3G, and ligating compatible ends in the pEGFP-C3
vector (Invitrogen). The micro-chimeras (F1-F2a/Cb and
F1-Ca/F2b) were generated using an internal BstEII restriction
site and exchanging sub-domains between APOBEC3C and
APOBEC3F2 (see Figure S1). The primers used to amplify
each individual domain and their respective restriction sites
are as follows (N represents any base):
3C:(F-KpnI)50-NNNGGTACCAACCCGATGAAGGCA-
ATGTAT-30, (R-XbaI) 50-NNNNTCTAGATCACTGGA-
GACTCTCCCG-30;
3F1:(F-XhoI)50-NNNCTCGAGATGAAGCCTCACTTC-
AGAAAC-30,(R-KpnI) 50-NNNNGGTACCTCTGAGAA-
TCTCCTTTAGCG-30;
3F2: (F-KpnI) 50-NNNGGTACCAACCCGATGGAGGC-
AATGTAT-30, (R-XbaI) 50-NNNTCTAGATCATTCGA-
GAATCTCCTGCAG-30;
3G1: (F-XhoI) 50-NNNCTCGAGATGAAGCCTCACTT-
CAGAAAC-30, (R-KpnI) 50-NNNGGTACCTCTGAGAA-
TCTCCCCCAGCAT-30;
3G2: (F-KpnI) 50-NNNGGTACCCACTCGATGGATCC-
ACCCAC-30, (R-XbaI) 50-NNNTCTAGATCAGTTTTCC-
TGATTCTGGAG-30.
RT–PCR
RNA was extracted from CEM or CEM-SS cells using
TRIZOL reagent (Gibco) according to the manufacturer’s
speciﬁcations. Ten micrograms of RNA were reverse-
transcribed using random hexamers (NEB) and Superscript
II reverse transcriptase (Invitrogen). APOBEC3F was ampli-
ﬁed using the following primers: (F): 50-CCTACGCAAAGC-
CCTATGGTGGAAC-30, (R): 50-CAGTATGTCGTCACAG-
AACCAAGAG-30. APOBEC3G was ampliﬁed using these
primers: (F): 50-CCACATAAACACGGTTTCCTTGAAG-30,
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primers are speciﬁc for APOBEC3F and APOBEC3G and
did not cross-react. APOBEC3C was ampliﬁed with the fol-
lowing primers: (F): 50-GAGGCCACCATGAATCCACAG-
ATCAGAAA-30,(R):50-TCCTGGTAACATGGATACTG-30.
Generation of virus-like particles
293T cells were co-transfected with Fugene 6 (Roche) at 70%
conﬂuence. FLAG- or eGFP-APOBEC encoding plasmids
were transfected at a 0.2:1 ratio with respect to CSGW and
at a 1:1 ratio with respect of M5P unless otherwise stated.
For HIV-1 infectivity assays, cells were co-transfected with
CSGW, p8.2 or p8.9 and pMDG at a 1:0.75:0.75 ratio. For
MLV production, the cells were transfected with M5P, pOGP
and pMDG at a 1:0.70:0.30 ratio. All transfections within the
same experiment were made-up to the same amount of total
DNA using pcDNA3.1 (Invitrogen). 293T cells were washed
the day following transfection with PBS and grown in culture
media for 48 h. Virus-containing supernatants were collected
72 h post-transfection and ﬁltered through a 0.45 mM ﬁlter.
Encapsidation
Viruses were produced as described in the previous section by
co-transfection of FLAG-APOBEC and virus expression vec-
tors. Supernatants were collected 72 h post-transfection and
293T packaging cells were harvested and assayed for FLAG-
APOBEC expression by immunoblot. Virus-containing super-
natants were pelleted through a 20% sucrose-PBS solution by
ultracentrifugation at 175000 g in a Beckman TLA-100.4
rotor for 1 h as described elsewhere (9). Virus pellets were
solubilized in RIPA buffer containing 0.5% NP-40. Virion and
cell lysates were analysed by western blot using a HRP-
conjugated anti-FLAG antibody (Sigma).
Viral sequence analysis
293T target cells were collected 48 h post-infection and
DNA was extracted using Puregene reagent (Gentra Systems)
according to the manufacturer’s speciﬁcations. DNA prepara-
tions were then treated with the restriction endonuclease DpnI
to eliminate any trace of plasmid carry-over from the transfec-
tion. DNA from MLV or HIV-1 infected cells were ampliﬁed
using the high ﬁdelity polymerase Pfu turbo(Stratagene) using
the following primers MLV: (F): 50-GGACCATCCTCTAG-
ACTGAAG-30; (R): 50-TAATCCGGATCTGTTAACGC-30;
HIV-1: (F): 50-ATGGTGAGCAAGGGCGAGGAG-30; (R):
50-ATCCCGGCGGCGGTCACGAAC-30. PCR products were
then gel puriﬁed and cloned using the TOPO-Blunt cloning kit
(Invitrogen) and sequenced using M13 reverse primers.
Southern blot
DNA was prepared from target 293T cells as described above.
Total DNA was then digested with BamHI and NotI restriction
endonucleases and resolved on a 1.2% agarose gel. DNA was
then transferred by capillarity to a Hybond N+ nylon mem-
brane and hybridized with a 32P-labeled eGFP cDNA probe for
16 h at 65 C. Membranes were washed three times for 30 min
in 0.1% SDS, 0.2· SSC and analyzed by phosphorImager.
Immunoprecipitations and western blots
Forproteinanalysis,cellswerelysedin10mMTris–HClpH8,
150 mM NaCl, 10% glycerol, 1% Nonidet P-40 supplemented
with protease inhibitors (Roche). EGFP fusion proteins were
immunoprecipitated using rabbit anti-GFP (5 mg/ml) (Abcam)
together with protein A-Sepharose beads (Amersham). EGFP
fusions were visualized by western blot using a HRP-
conjugated anti-GFP antibody at a 1:8000 dilution (Abcam),
whereas Vif was detected using a 1:1000 dilution of a mono-
clonal anti-Vif antibody (NIBSC, South Mimms, UK).
RESULTS
Anti-retroviral activity of APOBEC3C
Initial experiments revealed that APOBEC3C (like
APOBEC3F and APOBEC3G, but distinct from the related
cytidine deaminase AID) could be incorporated into MLV
virus-like particles (Figure 1A). This incorporation can indeed
have functional implications since APOBEC3C is able to
inhibit MLV infection and trigger G!A mutation of viral
replication intermediates (Figure 1B and C). The spectrum
of the mutations reveals that the target speciﬁcity is distinct
from that of both APOBEC3G (which essentially acts only
on CC dinucleotides) and APOBEC3F (which essentially
acts only on TC dinucleotides): APOBEC3C targets dCs
that are preceded by either dC or dT. In contrast, expression
of the AID deaminase in these assays gave little anti-viral
activity above that of the vector-only control and did not
yield any detectable mutation of MLV replication inter-
mediates (Figure 1B, bottom).
The precise mechanism by which the APOBEC3 proteins
restrict retroviral infectivity under physiological circumstan-
ces is uncertain. Various mechanisms have been suggested.
These include the possibilities that diminished infectivity is
simply a consequence of an excessive mutation load as well
as the suggestion that the incorporation of uracil into the
retroviral minus-strand cDNA might trigger its destruction
(16,48,49). We were therefore interested in ascertaining
whether APOBEC3C affected the persistence of viral DNA
following infection. Southern blot analysis revealed that all
three APOBEC3 members analyzed effected a substantial
decrease in the extent of retroviral DNA integration in the
infected cells using an MLV-based assay system, although
the three deaminases yielded substantially different loadings
of G!A mutation in the retroviral replication intermediates
under the same assay conditions (Figure 1D). Although we
cannot discriminate whether the viral DNA detected in the
Southern blots derives from sequences that have or have
not integrated into a host chromosome, the results nevertheless
reveal that co-transfection with APOBEC3 plasmids leads to a
diminished abundance of retroviral DNA in the target cell,
presumably reﬂecting degradation.
It is clearly interesting to know whether APOBEC3C can
also function as a restriction barrier to HIV-1 infection. We
ﬁnd that the APOBEC3C does exert an anti-viral effect
in an HIV-1-based assay system (similarly giving rise to
G!A mutation of viral replication intermediates) although
APOBEC3C-encoding plasmid is again somewhat less potent
than the APOBEC3F/G plasmids. This restriction of infection
Nucleic Acids Research, 2005, Vol. 33, No. 6 19151916 Nucleic Acids Research, 2005, Vol. 33, No. 6is at least in part relieved by the HIV-1 Vif gene product
(Figure 2A). Furthermore, cytoﬂuorometry experiments
performed using cells transfected with plasmids expressing
eGFP-tagged APOBEC3C with or without Vif-expressing
plasmids indicates that Vif does indeed mediate the desta-
bilization of APOBEC3C (Figure 2B). This destabilization
of APOBEC3C by Vif is somewhat surprising in view of
the fact that APOBEC3C bears high (81%) homology to
the C-terminal domain of APOBEC3F whereas mutational/
homology considerations (7–10,34) make it likely that it is
the N-terminal domain of APOBEC3F (to which APOBEC3C
shows only 53% homology) that interacts with Vif. In order
to ascertain whether the Vif-mediated destabilization does
indeed correlate with a Vif-APOBEC3C interaction, we per-
formed immunoprecipitation experiments. An interaction can
indeed be seen between the two proteins (Figure 2C).
If restriction of HIV-1 infection by endogenous (as opposed
to transfected and over-expressed) APOBEC3C also applies
invivo,then onemightexpectAPOBEC3Cnottobeexpressed
in cell-lines that are permissive for infection by Dvif HIV-1
particles. Indeed, the original discovery that an APOBEC3
family member acted as retroviral restriction elements was
based on the observation that Dvif HIV-1 can be propagated
in CEM-SS cells (a permissive T-cell line) but not in the non-
permissive CEM progenitor (1). RT–PCR analysis reveals that
APOBEC3C, APOBEC3F and APOBEC3G are all expressed
in CEM cells but that the expression of all three of them is
indeed lost in the CEM-SS derivative (Figure 2D).
The second domain of APOBEC3F and of
APOBEC3G encode the elements responsible
for deamination specificity
Since it is the second domain of APOBEC3F that is homo-
logous to the single-domained APOBEC3C, we wondered if
the catalytic speciﬁcity of APOBEC3F resided in its second
domain. One way to approach this issue (as it has been per-
formed with APOBEC3G) is to analyse whether mutations
likely to affect zinc coordination by either of the two domains
affects its catalytic activity. However, a problem with such
an approach is that retention of activity could mean that the
catalytic domain in question had not been inactivated; loss of
activity could be through general protein destabilization or
degradation. Therefore, in view of the fact that APOBEC3C,
APOBEC3F and APOBEC3G all exhibit different target
speciﬁcities, we asked whether replacing the second domain
of APOBEC3F by that of APOBEC3G or by APOBEC3C
could alter the target speciﬁcity of APOBEC3F. All chimeras
were readily expressed in 293T cells (Figure 3A) and gave
similar inhibition of viral infection as APOBEC3C (Figure 3B
and Table S2). The results on DNA deamination were straight-
forward. The target speciﬁcities of the resultant double-
domained APOBEC3 chimeras all accorded with that of the
C-terminal domain (Figure 3C).
An APOBEC3F second domain/APOBEC3C chimera
yields a novel target specificity
In order to further dissect the parts of the second domain of
APOBEC3F that mediate target speciﬁcity, we generated vari-
ants of ABOPEC3F (designated F1-Ca/F2b and F1-F2a/Cb,
respectively) in which the N- or C-terminal halves of the
APOBEC3F second domain were substituted by correspond-
ing portions from APOBEC3C. To our surprise, whilst both
chimeras were active in restricting MLV infection, they
yielded a mutation spectrum that was quite distinct from
both the APOBEC3F and APOBEC3C parents. They both
exhibitedastrong bias foraCatposition  1(similar,although
not quite as marked in extent, to the preference displayed by
APOBEC3G) (Figure 3D and Table S2).
Effects of single amino acid substitutions in the second
domain of APOBEC3F on target specificity
In order to gain more insight into the molecular basis of
the target site speciﬁcity of the APOBEC3 deaminases, we
tested the effects on speciﬁcity of single amino acid substitu-
tion in the C-terminal domain of APOBEC3F (Figure 4A and
Table S3). The nature of the mutations made was guided by
a comparison of the sequence of APOBEC3C with that of
APOBEC3F. Thus, mutations were made in residues that dif-
fered between APOBEC3F and APOBEC3C, so as to identify
those that could be responsible for a shift from the typical TC
deamination spectrum of APOBEC3F to the YC spectrum of
APOBEC3C. Of the 12 single amino-acid substitutions tested,
only APOBEC3F mutant 7 substantially altered the deamin-
ated spectrum at  1, whilst mutants 6 and 9 both gave some
modiﬁcation to the spectrum at position  2 (Figure 4B and
Table S3).
DISCUSSION
The results of this study clearly reveal that APOBEC3C
can work on both MLV and HIV-1. An antiviral effect of
Figure 1. APOBEC3Chas an anti-retroviral effect on MLV. (A) APOBEC3 proteins but not AID or U2AF are packaged in MLV virus-like particles. Virions were
produced by co-transfection of 293T cells with M5p, Gag-Pol, VSV-G and Flag-tagged APOBEC expression vectors. Three days after transfection, viruses were
isolatedfrom the supernatantby ultracentrifugation and producer cells were collected. Viral pellet and producercells were then lysedand submittedto western blot
analysisusinganti-FLAGHRP-conjugatedmonoclonalantibody.Sampleloadingwascontrolledusingananti-p30gagantibody.(B)Upperpanel:inhibitionofMLV
infection by various AID or APOBEC3 proteins. 293T cells were co-transfected with MLV producer plasmids in combinations with either of the FLAG-tagged
APOBEC3 or of the AID expression plasmids. Expression of eGFP was measured 48 h later by FACS analysis. Histograms represent the mean of at least three
independent experimentsand error bars represent the corresponding standard error. Lower panel: titration effect of various FLAG-tag APOBEC3proteins on MLV
infectivity. Increasing APOBEC3/AID:M5P ratios were used to co-transfect 293T cell. Only the amount of APOBEC3/AID plasmid was modified and the total
amountofDNAwasadjustedwithemptypCDNA3.1vector.EGFPexpressionwasmonitoredbyFACS48hpost-infection.Eachpointrepresentstheaverageoftwo
independent experiments. (C) Upper panel: mutation analysis of the MLV-encoded eGFP gene that successfully integrated into the genome of 293T target cells.
ViruseswereproducedinthepresenceofAPOBEC3C,APOBEC3ForAPOBEC3G.Numberscorrespondtothefrequencyinpercentageatwhichtheadjacentbases
are represented in the mutated sequences. ‘n’ represents the number of independent G!A mutations. Lower panel: sequences of the eGFP gene of MLV amplified
from 293T target cells. Vertical lines depict the relative locations of G!A mutations. (D) APOBEC3C, APOBEC3F and APOBEC3G inhibit viral genome
integration in target 293T cells. DNA was extracted from 293T cells infected with MLV virus-like particles, digested and a Southern blot analysis was performed
usinganeGFPcDNAprobetodetectviralDNAsequencesandagenomicAPOBEC2probeforsamplenormalization.Theethidiumbromide-stainedgelbeforeDNA
transfer is also shown.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1917Figure 2. APOBEC3C inhibits HIV infection and is sensitive to Vif. (A) Left panel: inhibition of HIV-1 and HIV-1 (Dvif) by various AID or APOBEC3 proteins.
293Tcellswereco-transfectedwithHIV-1orHIV-1(Dvif)producerplasmidsincombinationswitheitheroftheFLAG-taggedAPOBEC3oroftheAIDexpression
plasmids. Histograms represent the mean of at least three independent experiments and error bars represent the corresponding standard error. Right panel: titration
effectofvariousFLAG-taggedAPOBEC3proteinsonHIV-1(Dvif)infectivity.IncreasingAPOBEC3/AID:CSGWratioswereusedtoco-transfect293Tcell.Each
point represents the average of two independent experiments. (B) 293T cells were co-transfected with peGFP-C3, eGFP-APOBEC3C or eGFP-APOBEC3G and
plasmidsexpressingeitherViforDVif(Ctrl).Fluorescencewasmonitoredfor5daysbyFACSanalysis.Eachpointrepresentstheaverageandstandarderrorofthree
independentmeasurements.
*SignificantlydifferentbyStudent’st-test(P=0.007).(C)293Tcellswereco-transfectedwithpVifalone(Ctrl)orpVifandpeGFP-C3,
eGFP-APOBEC3CoreGFP-APOBEC3G,andcelllysateswereprepared48hlater.Thebulkofthelysatewassubmittedtoimmunoprecipitationwithananti-eGFP
monoclonal antibody. Immunoprecipitates and cell lysates were then submitted to SDS–PAGE and the western blots were probed with anti-Vif monoclonal
antibodies.(D)ExpressionofAPOBEC3C,APOBEC3FandAPOBEC3GinCEMandCEM-SScells.AnRT–PCRwasperformedonRNAisolatedfromeitherCEM
(upper panel) or CEM-SS (lower panel). Results reveal that the CEM-SS clone has lost the expression of APOBEC3C, -3F and -3G.
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in several (but not all) previous studies (28–30,33). Whilst
differences in the assay systems and retroviral substrates
used in the various studies might be a major contributing
factor, we suspect that the activity of APOBEC3C against
MLV and HIV-1 has not been previously highlighted because
it is evidently less potent against these retroviruses than are
APOBEC3F and APOBEC3G. Strikingly, in a recent study,
Yu et al. (29) have noted that APOBEC3C is very potent
against SIV.
Figure 3. The second domain of APOBEC3F and APOBEC3G enclose the elements governing deamination spectrum specificity. (A) Western blot analysis of the
differentchimericAPOBEC3proteins.AnHRP-conjugatedanti-eGFPantibodywasusedtorevealthebands.(B)F1CandF1G2chimericAPOBEC3proteinsshow
a strong antiviral effect on MLV virus-like particles. Histograms represent the mean of three independent experiments and error bars represent the standard error.
(CandD)SchematicrepresentationofthedifferentchimericAPOBEC3Fproteinsandtheirrespectivedeaminationspectrumatpositions 2and 1inrelationtothe
deaminated dC is depicted in pie charts. ‘n’ represents the number of independent G!A mutations.
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acts as a viral restriction element in vivo. This is a difﬁcult
issue to address by asking whether APOBEC3C leaves a
footprint on the mutation spectrum of naturally occurring
hypermutated HIV-1 sequences since the target speciﬁcity
of APOBEC3C is likely to show some overlap with that of
APOBEC3F. However, it is notable that co-transfection with
Vif can overcome APOBEC3C-mediated restriction of HIV-1
(29) and, as we show here, Vif and APOBEC3C can partake in
an interaction that correlates with APOBEC3C degradation.
This is somewhat remarkable in light of the fact that, at least in
the case of APOBEC3G, distinct domains seem to be largely
responsible for Vif binding and for dominant catalytic activity
[(6–10) and see below].
Despite inducing mutations at a frequency several-fold
lower than APOBEC3G or APOBEC3F, APOBEC3C is
still capable of inhibiting viral infection and blocking viral
DNA persistence in the target cells. The precise mechanism
by which APOBEC3 proteins inhibit retroviral infection is
not known, but it is possible that the extent of inhibition of
retroviral integration does not correlate simply with the extent
of retroviral deamination. Interestingly, although G!A muta-
tionsintheHBVgenomehavebeenobservedincertainexperi-
mental conditions and also in clinical samples (50,51), it has
been proposed by Turelli et al. (52) that APOBEC3G-
mediated inhibition of HBV infection could be independent
of deamination. Somewhat analogous observations have been
made by Newman et al. with regard to HIV-1 (53). These
Figure 4. ThedeaminationspectrumofAPOBEC3Fisalteredbysingleaminoacidsubstitutions.(A)SequencealignmentofAPOBEC3Candtheseconddomainof
APOBEC3F. Numbers indicate residues that were changed to generate the 12 mutant APOBEC3F proteins. (B) Histograms depicting the proportion of each
nucleotide at positions  2 and  1 in relation to the deaminated dC.
1920 Nucleic Acids Research, 2005, Vol. 33, No. 6results hint that there may be other (not deamination-based)
mechanisms by which APOBEC3 proteins hinder viral infec-
tion.
It has been somewhat unclear as to whether catalytic
activity is contained within either or both the domains of
the double-domained deaminases (17,20,44). In studies of
APOBEC3G, several single ordouble amino acid substitutions
have been found to lead to diminished accumulation of G!A
mutations in the retroviral target although, as noted by Shindo
et al. (44), this diminished activity can often be correlated
with diminished protein stability, in particular when working
with truncated forms of these deaminases (6). Interestingly,
however, none of the amino acid substitutions generated
in APOBEC3G to date have been found to be sufﬁcient to
destroy all deaminating activity although mutations within the
catalytic site of the second domain were found to lead to a
complete loss of antiviral activity (17,20,44). Here, we have
investigated the target site speciﬁcities of various chimeric
APOBEC3s in order to identify which parts of the proteins
are implicated in catalytic activity. The results reveal that the
second domain of APOBEC3F and APOBEC3G play a critical
role in determining the target speciﬁcity of these deaminases
with regards to sensitivity to 50-ﬂanking nucleotides. It is dif-
ﬁcult to imagine any interpretation other than that these
domainsarecatalyticallyactive,althoughwe obviouslycannot
exclude the possibility that the N-terminal domains of these
deaminases also exhibit some (but probably much lesser)
activity. [During the course of this work, we also generated
chimeras in which the N-terminal domain of APOBEC3G was
fused with the C-terminal domain of APOBEC3F or with
APOBEC3C, but these proteins turned out to be unstable
(data not shown) and therefore gave no insight into the pos-
sible catalytic activity of the N-terminal domains.]
We also generated deaminases carrying a chimeric
C-terminal domain composed of part APOBEC3C and part
APOBEC3F-second domain in order to gain insight into
the different target site preferences conferred by these two
domains. To our surprise, the hybrids exhibited a target spe-
ciﬁcity closer to that of APOBEC3G than that of either parent.
Furthermore,analysisofAPOBEC3Fpointmutantsrevealthat
sensitivity to 50-ﬂanking nucleotides can be modiﬁed by
distinct single amino acid substitutions. Whilst a deﬁnitive
interpretation of these mutations must await the elucidation
of the three-dimensional structure of APOBEC3 deaminases,
the results demonstrate that target site preference can be easily
perturbed and strongly suggest that this preference must be
sensitive to relatively subtle changes in deaminase structure.
It is striking that all four antiviral APOBEC3 deaminases
(APOBEC3B, -3C, -3F and 3G) that have been characterized
to date display different DNA target site speciﬁcities. The
precise signiﬁcance of retroviral deamination to the physio-
logical functioning of the APOBEC3 proteins isstill uncertain.
It is therefore difﬁcult to know whether the differing target
site preferences of the various APOBEC3 proteins reﬂect
differences that were selected during evolution because the
local targeting of deamination is intimately associated with
the functioning of these proteins in restricting viral infection
(35,54). An alternative possibility, given the ease with which
the target site preference is perturbed, is that the differing
mutational speciﬁcities of these proteins are incidental by-
products of changes, possibly located outside the immediate
vicinity of the active site, that have been selected for other
reasons (e.g. a modulation of protein–proteininteractions so as
to avoid viral counter-measures).
It is interesting in this context to compare the target
site preference of the APOBEC3 proteins to that of AID
(activation-induced deaminase) which functions in the adapt-
ive immune system to trigger antibody gene diversiﬁcation
(55,56). AID has a quite distinct target site preference from
the APOBEC3 proteins, preferring a purine upstream of the
targeted dC (57–59). The deamination preference of AID will
presumably have co-evolved with the sequences of its physio-
logical targets (the variable and switch regions of the immuno-
globulin loci) so as to allow both optimal targeting of somatic
mutations during antibody afﬁnity maturation and efﬁcient
class switch recombination (60,61). The structural basis for
major difference in target speciﬁcity of AID and APOBEC3
proteins is currently unknown. Strikingly, in a recent muta-
genesis study of AID, Bransteitter et al. (62) have similarly
concluded that a single amino acid substitution outside the
catalytic site (in fact located in the N-terminal region of
this protein) can affect mutational speciﬁcity.
Both this study and that of Bransteitter et al. (62) reveal
that it is relatively easy to generate altered AID/APOBEC
family deaminases that exhibit novel mutational speciﬁcities.
AID-mediated DNA deamination not only underpins the
physiological mechanism of antibody afﬁnity maturation,
it also underpins several in vitro strategies that exploit an
iterative alternation of mutation and selection to derive pro-
teins with desired characteristics (63–65). The functional
diversity in these in vitro systems is signiﬁcantly restricted
by the limited mutational speciﬁcity of the DNA deaminase:
generating a range of deaminases with differing (and possibly
more relaxed) target speciﬁcities could therefore prove of
some utility.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
ACKNOWLEDGEMENTS
We thank the Centralized Facility for AIDS Reagents for
monoclonal anti-Vif antibodies and the NIBSC for providing
theCEM-SScellline.WealsothankChristinaRadaforhelpful
discussions and experimentaladvice. Thiswork was supported
by a grant from the Leukaemia Research Fund to M.S.N.
M.A.L. is a recipient of a postdoctoral fellowship award
from the Fond de Recherche en Sante du Quebec (FRSQ).
S.G.C. was supported by a Marie Curie Fellowship of the
European Community programme FP5 under contract number
MCFI-2002–01357. Funding to pay the Open Access publica-
tion charges for this article was provided by the UK Medical
Research Council.
Conflict of interest statement. None declared.
REFERENCES
1. Sheehy,A.M., Gaddis,N.C., Choi,J.D. and Malim,M.H. (2002) Isolation
of a human gene that inhibits HIV-1 infection and is suppressed by the
viral Vif protein. Nature, 418, 646–650.
Nucleic Acids Research, 2005, Vol. 33, No. 6 19212. Marin,M., Rose,K.M., Kozak,S.L. and Kabat,D. (2003) HIV-1 Vif
protein binds the editing enzyme APOBEC3G and induces its
degradation. Nature Med., 9, 1398–1403.
3. Stopak,K., de Noronha,C., Yonemoto,W. and Greene,W.C. (2003)
HIV-1VifblockstheantiviralactivityofAPOBEC3Gbyimpairingboth
its translation and intracellular stability. Mol. Cell, 12, 591–601.
4. Sheehy,A.M., Gaddis,N.C. and Malim,M.H. (2003) The antiretroviral
enzyme APOBEC3G is degraded by the proteasome in response to
HIV-1 Vif. Nature Med., 9, 1404–1407.
5. Yu,X., Yu,Y., Liu,B., Luo,K., Kong,W., Mao,P. and Yu,X.F. (2003)
Induction of APOBEC3G ubiquitination and degradation by an
HIV-1 Vif-Cul5-SCF complex. Science, 302, 1056–1060.
6. Conticello,S.G., Harris,R.S. and Neuberger,M.S. (2003) The Vif protein
of HIV triggersdegradation of the humanantiretroviralDNA deaminase
APOBEC3G. Curr. Biol., 13, 2009–2013.
7. Schrofelbauer,B., Chen,D. and Landau,N.R. (2004) A single amino acid
of APOBEC3G controls its species-specific interaction with virion
infectivity factor (Vif). Proc. Natl Acad. Sci. USA, 101, 3927–3932.
8. Xu,H., Svarovskaia,E.S., Barr,R., Zhang,Y., Khan,M.A., Strebel,K. and
Pathak,V.K. (2004) A single amino acid substitution in human
APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion
infectivity factor-induced depletion. Proc. Natl Acad. Sci. USA, 101,
5652–5657.
9. Bogerd,H.P., Doehle,B.P., Wiegand,H.L. and Cullen,B.R. (2004)
A single amino acid difference in the host APOBEC3G protein controls
the primate species specificity of HIV type 1 virion infectivity factor.
Proc. Natl Acad. Sci. USA, 101, 3770–3774.
10. Mangeat,B.,Turelli,P.,Liao,S.andTrono,D.(2004)Asingleaminoacid
determinant governs the species-specific sensitivity of APOBEC3G to
Vif action. J. Biol. Chem., 279, 14481–14483.
11. Alce,T.M. and Popik,W. (2004) APOBEC3G is incorporated into
virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid
protein. J. Biol. Chem., 279, 34083–34086.
12. Cen,S., Guo,F., Niu,M., Saadatmand,J., Deflassieux,J. and Kleiman,L.
(2004) The interaction between HIV-1 Gag and APOBEC3G.
J. Biol. Chem., 279, 33177–33184.
13. Douaisi,M., Dussart,S., Courcoul,M., Bessou,G., Vigne,R. and
Decroly,E.(2004) HIV-1 and MLV Gag proteins are sufficient to recruit
APOBEC3Gintovirus-likeparticles.Biochem.Biophys. Res.Commun.,
321, 566–573.
14. Luo,K., Liu,B., Xiao,Z., Yu,Y., Yu,X., Gorelick,R. and Yu,X.F. (2004)
Amino-terminal region of the human immunodeficiency virus type 1
nucleocapsid is required for human APOBEC3G packaging. J. Virol.,
78, 11841–11852.
15. Schafer,A., Bogerd,H.P. and Cullen,B.R. (2004) Specific packaging of
APOBEC3GintoHIV-1virionsismediatedbythenucleocapsiddomain
of the gag polyprotein precursor. Virology, 328, 163–168.
16. Harris,R.S., Bishop,K.N., Sheehy,A.M., Craig,H.M.,
Petersen-Mahrt,S.K.,Watt,I.N.,Neuberger,M.S.andMalim,M.H.(2003)
DNA deamination mediates innate immunity to retroviral infection.
Cell, 113, 803–809.
17. Mangeat,B., Turelli,P., Caron,G., Friedli,M., Perrin,L. and Trono,D.
(2003) Broad antiretroviral defence by human APOBEC3G through
lethal editing of nascent reverse transcripts. Nature, 424, 99–103.
18. Yu,Q., Konig,R., Pillai,S., Chiles,K., Kearney,M., Palmer,S.,
Richman,D., Coffin,J.M. and Landau,N.R. (2004) Single-strand
specificityofAPOBEC3Gaccountsforminus-stranddeaminationofthe
HIV genome. Nature Struct. Mol. Biol., 11, 435–442.
19. Lecossier,D., Bouchonnet,F., Clavel,F. and Hance,A.J. (2003)
Hypermutation of HIV-1 DNA in the absence of the Vif protein.
Science, 300, 1112.
20. Zhang,H., Yang,B., Pomerantz,R.J., Zhang,C., Arunachalam,S.C. and
Gao,L.(2003)ThecytidinedeaminaseCEM15induceshypermutationin
newly synthesized HIV-1 DNA. Nature, 424, 94–98.
21. Harris,R.S., Petersen-Mahrt,S.K. and Neuberger,M.S. (2002)
RNA editing enzyme APOBEC1 and some of its homologs can act
as DNA mutators. Mol. Cell, 10, 1247–1253.
22. Mariani,R., Chen,D., Schrofelbauer,B., Navarro,F., Konig,R.,
Bollman,B., Munk,C., Nymark-McMahon,H. and Landau,N.R. (2003)
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
Cell, 114, 21–31.
23. Vartanian,J.P., Meyerhans,A., Asjo,B. and Wain-Hobson,S. (1991)
Selection, recombination, and G->A hypermutation of human
immunodeficiency virus type 1 genomes. J. Virol., 65, 1779–1788.
24. Fitzgibbon,J.E., Mazar,S. and Dubin,D.T. (1993) A new type of G–>A
hypermutation affecting human immunodeficiency virus. AIDS Res.
Hum. Retroviruses, 9, 833–838.
25. Borman,A.M., Quillent,C., Charneau,P., Kean,K.M. and Clavel,F.
(1995) A highly defective HIV-1 group O provirus: evidence for the
role of local sequence determinants in G–>A hypermutation during
negative-strand viral DNA synthesis. Virology, 208, 601–609.
26. Janini,M., Rogers,M., Birx,D.R. and McCutchan,F.E. (2001) Human
immunodeficiency virus type 1 DNA sequences genetically damaged by
hypermutation are often abundant in patient peripheral blood
mononuclear cells and may be generated during near-simultaneous
infection and activation of CD4(+) T cells. J. Virol., 75, 7973–7986.
27. Vartanian,J.P., Henry,M. and Wain-Hobson,S. (2002) Sustained
G–>A hypermutation during reverse transcription of an entire human
immunodeficiency virus type 1 strain Vau group O genome.
J. Gen. Virol., 83, 801–805.
28. Zheng,Y.H., Irwin,D., Kurosu,T., Tokunaga,K., Sata,T. and
Peterlin,B.M. (2004) Human APOBEC3F is another host factor that
blocks human immunodeficiency virus type 1 replication. J. Virol.,
78, 6073–6076.
29. Yu,Q., Chen,D., Konig,R., Mariani,R., Unutmaz,D. and Landau,N.R.
(2004) APOBEC3B and APOBEC3C are potent inhibitors of simian
immunodeficiency virus replication. J. Biol. Chem., 279,
53379–53386.
30. Wiegand,H.L., Doehle,B.P., Bogerd,H.P. and Cullen,B.R. (2004)
A second human antiretroviral factor, APOBEC3F, is suppressed by
the HIV-1 and HIV-2 Vif proteins. EMBO Rep., 23, 2451–2458.
31. Liddament,M.T., Brown,W.L., Schumacher,A.J. and Harris,R.S. (2004)
APOBEC3F properties and hypermutation preferences indicate activity
against HIV-1 in vivo. Curr. Biol., 14, 1385–1391.
32. Gaddis,N.C., Sheehy,A.M., Ahmad,K.M., Swanson,C.M., Bishop,K.N.,
Beer,B.E.,Marx,P.A.,Gao,F.,Bibollet-Ruche,F.,Hahn,B.H.etal.(2004)
Further investigation of simian immunodeficiency virus Vif function
in human cells. J. Virol., 78, 12041–12046.
33. Bishop,K.N., Holmes,R.K., Sheehy,A.M., Davidson,N.O., Cho,S.J. and
Malim,M.H. (2004) Cytidine deamination of retroviral DNA by diverse
APOBEC proteins. Curr. Biol., 14, 1392–1396.
34. Jarmuz,A., Chester,A., Bayliss,J., Gisbourne,J., Dunham,I., Scott,J. and
Navaratnam,N. (2002) An anthropoid-specific locus of orphan C to U
RNA-editing enzymes on chromosome 22. Genomics, 79,
285–296.
35. Zhang,J. and Webb,D.M. (2004) Rapid evolution of primate antiviral
enzyme APOBEC3G. Hum. Mol. Genet., 13, 1785–1791.
36. Conticello,S.G., Thomas,C.J., Petersen-Mahrt,S. and Neuberger,M.S.
(2004) Evolution of the AID/APOBEC family of polynucleotide
(deoxy)cytidine deaminases. Mol. Biol. Evol., 22, 367–377.
37. Wedekind,J.E., Dance,G.S., Sowden,M.P. and Smith,H.C. (2003)
Messenger RNA editing in mammals: new members of the APOBEC
family seeking roles in the family business. Trends Genet., 19,
207–216.
38. Yamanaka,S., Poksay,K.S., Balestra,M.E., Zeng,G.Q. and
Innerarity,T.L. (1994) Cloning and mutagenesis of the rabbit ApoB
mRNA editing protein. A zinc motif is essential for catalytic activity,
and noncatalytic auxiliary factor(s) of the editing complex are widely
distributed. J. Biol. Chem., 269, 21725–21734.
39. Navaratnam,N., Bhattacharya,S., Fujino,T., Patel,D., Jarmuz,A.L. and
Scott,J. (1995) Evolutionary origins of apoB mRNA editing: catalysis
by a cytidine deaminase that has acquired a novel RNA-binding
motif at its active site. Cell, 81, 187–195.
40. MacGinnitie,A.J., Anant,S. and Davidson,N.O. (1995) Mutagenesis of
apobec-1, the catalytic subunit of the mammalian apolipoprotein B
mRNA editing enzyme, reveals distinct domains that mediate cytosine
nucleoside deaminase, RNA binding, and RNA editing activity.
J. Biol. Chem., 270, 14768–14775.
41. Betts,L., Xiang,S., Short,S.A., Wolfenden,R. and Carter,C.W.,Jr (1994)
Cytidine deaminase. The 2.3 s crystal structure of an enzyme:
transition-state analog complex. J. Mol. Biol., 235, 635–656.
42. Carlow,D.C., Carter,C.W.,Jr, Mejlhede,N., Neuhard,J. and
Wolfenden,R. (1999) Cytidine deaminases from B. subtilis and E. coli:
compensating effects of changing zinc coordination and quaternary
structure. Biochemistry (Mosc.), 38, 12258–12265.
43. Ireton,G.C., McDermott,G., Black,M.E. and Stoddard,B.L. (2002)
The structure of Escherichia coli cytosine deaminase. J. Mol. Biol.,
315, 687–697.
1922 Nucleic Acids Research, 2005, Vol. 33, No. 644. Shindo,K., Takaori-Kondo,A., Kobayashi,M., Abudu,A., Fukunaga,K.
and Uchiyama,T. (2003) The enzymatic activity of CEM15/Apobec-3G
is essential for the regulation of the infectivity of HIV-1 virion but not a
sole determinant of its antiviral activity. J. Biol. Chem., 278,
44412–44416.
45. Demaison,C., Parsley,K., Brouns,G., Scherr,M., Battmer,K., Kinnon,C.,
Grez,M. and Thrasher,A.J. (2002) High-level transduction and gene
expression in hematopoietic repopulating cells using a human
immunodeficiency virus type 1-based lentiviral vector containing
an internal spleen focus forming virus promoter. Hum. Gene Ther.,
13, 803–813.
46. Besnier,C.,Takeuchi,Y.andTowers,G.(2002)Restrictionoflentivirusin
monkeys. Proc. Natl Acad. Sci. USA, 99, 11920–11925.
47. Naldini,L., Blomer,U., Gallay,P., Ory,D., Mulligan,R., Gage,F.H.,
Verma,I.M. and Trono,D. (1996) In vivo gene delivery and stable
transduction of nondividing cells by a lentiviral vector. Science,
272, 263–267.
48. Gu,Y. and Sundquist,W.I. (2003) Good to CU. Nature, 424, 21–22.
49. Vartanian,J.P., Sommer,P. and Wain-Hobson,S. (2003) Death and the
retrovirus. Trends Mol. Med., 9, 409–413.
50. Noguchi,C., Ishino,H., Tsuge,M., Fujimoto,Y., Imamura,M.,
Takahashi,S. and Chayama,K. (2005) G to A hypermutation of hepatitis
B virus. Hepatology, 41, 626–633.
51. Rosler,C., Kock,J., Malim,M.H., Blum,H.E. and von Weizsacker,F.
(2004) Comment on ‘Inhibition of hepatitis B virus replication by
APOBEC3G’. Science, 305, 1403.
52. Turelli,P.,Mangeat,B.,Jost,S.,Vianin,S.andTrono,D.(2004)Inhibition
of hepatitis B virus replication by APOBEC3G. Science, 303, 1829.
53. Newman,E.N., Holmes,R.K., Craig,H.M., Klein,K.C., Lingappa,J.R.,
Malim,M.H.andSheehy,A.M.(2005)AntiviralfunctionofAPOBEC3G
can be dissociated from cytidine deaminase activity. Curr. Biol., 15,
166–170.
54. Sawyer,S.L., Emerman,M. and Malik,H.S. (2004) Ancient adaptive
evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
PLoS Biol., 2, E275.
55. Muramatsu,M., Kinoshita,K., Fagarasan,S., Yamada,S., Shinkai,Y. and
Honjo,T. (2000) Class switch recombination and hypermutation require
activation-induced cytidine deaminase (AID), a potential RNA editing
enzyme. Cell, 102, 553–563.
56. Neuberger,M.S.,Harris,R.S.,DiNoia,J.andPetersen-Mahrt,S.K.(2003)
Immunity through DNA deamination. Trends Biochem. Sci., 28,
305–312.
57. Chaudhuri,J., Tian,M., Khuong,C., Chua,K., Pinaud,E. and Alt,F.W.
(2003) Transcription-targeted DNA deamination by the AID antibody
diversification enzyme. Nature, 422, 726–730.
58. Pham,P., Bransteitter,R., Petruska,J. and Goodman,M.F. (2003)
ProcessiveAID-catalysedcytosinedeaminationonsingle-strandedDNA
simulates somatic hypermutation. Nature, 424, 103–107.
59. Beale,R.C., Petersen-Mahrt,S.K., Watt,I.N., Harris,R.S., Rada,C. and
Neuberger,M.S. (2004) Comparison of the differential context-
dependenceofDNAdeaminationbyAPOBECenzymes:correlationwith
mutation spectra in vivo. J. Mol. Biol., 337, 585–596.
60. Zarrin,A.A., Alt,F.W., Chaudhuri,J., Stokes,N., Kaushal,D.,
Du Pasquier,L. and Tian,M. (2004) An evolutionarily conserved target
motifforimmunoglobulinclass-switchrecombination.NatureImmunol.,
5, 1275–1281.
61. Wagner,S.D.,Milstein,C.andNeuberger,M.S.(1995)Codonbiastargets
mutation. Nature, 376, 732.
62. Bransteitter,R., Pham,P., Calabrese,P. and Goodman,M.F. (2004)
Biochemical analysis of hypermutational targeting by wild type and
mutant activation-induced cytidine deaminase. J. Biol. Chem.,
279, 51612–51621.
63. Cumbers,S.J., Williams,G.T., Davies,S.L., Grenfell,R.L., Takeda,S.,
Batista,F.D., Sale,J.E. and Neuberger,M.S. (2002) Generation and
iterative affinity maturation of antibodies in vitro using hypermutating
B-cell lines. Nat. Biotechnol., 20, 1129–1134.
64. Martin,A., Bardwell,P.D., Woo,C.J., Fan,M., Shulman,M.J. and
Scharff,M.D. (2002) Activation-induced cytidine deaminase turns
on somatic hypermutation in hybridomas. Nature, 415,
802–806.
65. Wang,L., Jackson,W.C., Steinbach,P.A. and Tsien,R.Y. (2004)
Evolution of new nonantibody proteins via iterative somatic
hypermutation. Proc. Natl Acad. Sci. USA, 101,
16745–16749.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1923